Clinical Trial Search

Phase 3 N=61 Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH

X-Linked Hypophosphatemia

Primary: Radiographic Global Impression of Change (RGI-C) Global Score at Week 40 — 0.77; 1.92 score on a scale — p=< 0.0001

Kyowa Kirin, Inc. Results Apr 2019 8.2% serious AE View details

Phase 3 N=372 Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Cutaneous T-Cell Lymphoma

Primary: Progression Free Survival — 55.3; 28.8; 38.3; 15.3 percentage of subjects

Kyowa Kirin, Inc. Results Apr 2019 30.7% serious AE View details

Phase 3 N=202 A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

Primary: Assessment of Systemic Lupus Erythematosus Responder Index (SRI) at Week 52 — 52.5; 44.6 percentage of patient responder — p=0.2631

ImmuPharma Results Apr 2019 14.4% serious AE View details

Phase 3 N=559 A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)

Non-small Cell Lung Cancer

Primary: Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 6.4; 4.8 Months — p=<0.0001

Merck Sharp & Dohme LLC Results Apr 2019 40.5% serious AE View details

Phase 3 N=88 A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

Hemophilia A

Primary: Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants <12 Years of Age — 0.3 treated bleed rate per year

Hoffmann-La Roche Results Apr 2019 30.7% serious AE View details

Phase 3 N=1,250 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

Bacterial Infections · Virus Diseases

Primary: Percentage of Participants Vaccinated With PR5I With Acceptable Antibody (Ab) Response to Haemophilus Influenzae Type b, Diphtheria, Tetanus, and Poliovirus Types 1, 2 &…

MCM Vaccines B.V. Results Apr 2019 3.7% serious AE View details

Phase 3 N=350 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis

Spondylitis, Ankylosing

Primary: Percentage of Participants Responded for Assessment of Spondyloarthritis International Society 20 Criteria (ASAS20) at 16 Weeks — 60.5; 65.5; 49.1 percentage of…

Novartis Pharmaceuticals Results Apr 2019 10.9% serious AE View details

Phase 3 N=1,224 Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

Hepatitis C

Primary: Number of Participants Achieving Responder Status at 24 Weeks of Treatment — 80; 87; 90; 59 Participants — p=0.078

Merck Sharp & Dohme LLC Results Apr 2019 10.6% serious AE View details

Phase 3 N=26 Actinic Keratoses Treatment With Metvix® in Combination With Light

Actinic Keratoses

Primary: Mean Change From Baseline in Total Number of Treated Mild Lesions Per Side at Week 12 — 19.6; 20.0 number of lesions — p=0.8460

University Hospital, Limoges Results Apr 2019 7.7% serious AE View details

Phase 3 N=334 Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS

HIV-1 Infection

Primary: Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART — 19.7; 49.8 Cumulative events per 100 persons

Advancing Clinical Therapeutics Globally for… Results Apr 2019 43.2% serious AE View details

Phase 3 N=374 A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine

Pain

Primary: Time Weighted Sum of Pain Relief Rating (PRR) and Pain Intensity Difference (PID) Scores From 0 to 8 Hours Post-dose (SPRID 0-8): Ibuprofen + Caffeine Versus Ibuprofen…

Pfizer Results Apr 2019 0.0% serious AE View details

Phase 3 N=994 Effects of Abatacept in Patients With Early Rheumatoid Arthritis

Rheumatoid Arthritis

Primary: Percentage of Participants in Simple Disease Activity Index (SDAI) Remission at Week 24 — 21.3; 16.0 Percentage of participants — p=0.2359

Bristol-Myers Squibb Results Apr 2019 5.6% serious AE View details

Phase 3 N=182 Efficacy and Safety Clinical Trial of Tenoten for Children Liquid Dosage Form Therapy in Infants With Sequelae of Perinatal Brain Injury

Sequelae of Perinatal Brain Injury

Primary: Percentage of Patients With a 4 and More Point Increase of the Total Score According to Jurba-Mastyukova Psychomotor Development Scale by the End of the Treatment…

Materia Medica Holding Results Apr 2019 0.5% serious AE View details

Phase 3 N=745 Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Keratoconjunctivitis Sicca

Primary: Tear Production — 16.6; 9.2 Percentage of eyes

Sun Pharmaceutical Industries Limited Results Apr 2019 1.1% serious AE View details

Phase 3 N=180 Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin

Neck Pain · Back Pain · Spasm

Primary: Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Day 3 of Treatment — 20.0; 28.9; 60.0; 46.7 percentage of participants — p=0.6179

Takeda Results Apr 2019 0.0% serious AE View details